TY  - JOUR
A1  - Deak, Dalma
A1  - Pop, Cristina
A1  - Zimta, Alina-Andreea
A1  - Jurj, Ancuta
A1  - Ghiaur, Alexandra
A1  - Pasca, Sergiu
A1  - Teodorescu, Patric
A1  - Dascalescu, Angela
A1  - Antohe, Ion
A1  - Ionescu, Bogdan
A1  - Constantinescu, Catalin
A1  - Onaciu, Anca
A1  - Munteanu, Raluca
A1  - Berindan-Neagoe, Ioana
A1  - Petrushev, Bobe
A1  - Turcas, Cristina
A1  - Iluta, Sabina
A1  - Selicean, Cristina
A1  - Zdrenghea, Mihnea
A1  - Tanase, Alina
A1  - Danaila, Catalin
A1  - Colita, Anca
A1  - Colita, Andrei
A1  - Dima, Delia
A1  - Coriu, Daniel
A1  - Einsele, Hermann
A1  - Tomuleasa, Ciprian
T1  - Let’s Talk About BiTEs and Other Drugs in the Real-Life Setting for B-Cell Acute Lymphoblastic Leukemia
JF  - Frontiers in Immunology
N2  - Background: Therapy for acute lymphoblastic leukemia (ALL) are currently initially efficient, but even if a high percentage of patients have an initial complete remission (CR), most of them relapse. Recent data shows that immunotherapy with either bispecific T-cell engagers (BiTEs) of chimeric antigen receptor (CAR) T cells can eliminate residual chemotherapy-resistant B-ALL cells.
Objective: The objective of the manuscript is to present improvements in the clinical outcome for chemotherapy-resistant ALL in the real-life setting, by describing Romania's experience with bispecific antibodies for B-cell ALL.
Methods: We present the role of novel therapies for relapsed B-cell ALL, including the drugs under investigation in phase I-III clinical trials, as a potential bridge to transplant. Blinatumomab is presented in a critical review, presenting both the advantages of this drug, as well as its limitations.
Results: Bispecific antibodies are discussed, describing the clinical trials that resulted in its approval by the FDA and EMA. The real-life setting for relapsed B-cell ALL is described and we present the patients treated with blinatumomab in Romania.
Conclusion: In the current manuscript, we present blinatumomab as a therapeutic alternative in the bridge-to-transplant setting for refractory or relapsed ALL, to gain a better understanding of the available therapies and evidence-based data for these patients in 2019.
KW  - blinatumoman
KW  - acute lymphoblastic leukemia
KW  - bridge-to-transplant
KW  - real life setting
KW  - bispecific antobodies
Y1  - 2019
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-193921
SN  - 1664-3224
VL  - 10
IS  - 2856
ER  - 
TY  - JOUR
A1  - Constantinescu, Catalin
A1  - Pasca, Sergiu
A1  - Zimta, Alina-Andreea
A1  - Tat, Tiberiu
A1  - Rus, Ioana
A1  - Teodorescu, Patric
A1  - Iluta, Sabina
A1  - Tanase, Alina
A1  - Colita, Anca
A1  - Sigurjonsson, Olafur
A1  - Einsele, Hermann
A1  - Tomuleasa, Ciprian
T1  - Overview of the side-effects of FDA- and/or EMA-approved targeted therapies for the treatment of hematological malignancies
JF  - Journal of Clinical Medicine
N2  - In the last decade there has been tremendous effort in offering better therapeutic management strategies to patients with hematologic malignancies. These efforts have ranged from biological to clinical approaches and resulted in the rapid development of new approaches. The main “problem” that comes with the high influx of newly approved drugs, which not only influences hematologists that frequently work with these drugs but also affects other healthcare professionals that work with hematologists in patient management, including intensive care unit (ICU) physicians, is they have to keep up within their specialty and, in addition, with the side-effects that can occur when encountering hematology-specific therapies. Nonetheless, there are few people that have an in-depth understanding of a specialty outside theirs. Thus, this manuscript offers an overview of the most common side-effects caused by therapies used in hematology nowadays, or that are currently being investigated in clinical trials, with the purpose to serve as an aid to other specialties. Nevertheless, because of the high amount of information on this subject, each chapter will offer an overview of the side-effects of a drug class with each reference of the section being intended as further reading.
KW  - novel therapies
KW  - life-threatening side-effects
KW  - hematological malignancies
Y1  - 2020
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-213020
SN  - 2077-0383
VL  - 9
IS  - 9
ER  -